3rd Quarter - Report

BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY

Period 3rd Quarter 2016 Filed Oct 19, 2016 Signed by Chris Pernie

Official filing
Firm
BRISTOL-MYERS SQUIBB COMPANY
Client
BRISTOL-MYERS SQUIBB COMPANY
Income
—
Expenses
$810,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Labor, Health and Human Services, Education, and Related Agencies Appropriations Bill, regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative and Senate Innovation for a Healthier America proposal, regarding all biopharmaceutical related provisions. No Bill, lobbied Congress on biosimilar issues including naming, labeling and interchangeability. No Bill, lobbied Congress on importation of prescription drugs. S. 2912, Trickett Wendler Right to Try Act of 2016, S. 2912, regarding all biopharmaceutical related provisions. S. 3056, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016, regarding all biopharmaceutical related provisions. No Bill, Prescription Drug User Fee Act, regarding all biopharmaceutical related provisions. No Bill, Biosimilar User Fee Act, regarding all biopharmaceutical related provisions. S. 3335/H.R. 6043 the Fair Accountability and Innovative Research Drug Pricing Act, regarding all biopharmaceutical related provisions.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); SENATE

Bills named: S. 3335 (114th), S. 2912 (114th), H.R. 6 (114th), S. 3056 (114th), H.R. 6043 (114th), H.R. 1078 (114th)

Trade (domestic/foreign) TRD

S. 995, H.R. 2146 Bipartisan Congressional Trade Priorities and Accountability Act, regarding intellectual property rights in trade agreements and international negotiations. Trans-Pacific Partnership Trade Agreement, regardng all biopharmaceutical related provisions.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: Commerce, Dept of (DOC); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 995 (114th), H.R. 2146 (114th)

Copyright/Patent/Trademark CPT

HR 9, the Innovation Act, regarding all biopharmaceutical related provisions. S. 1137, Protecting American Talent and Entrepreneurship Act, regarding all biopharmaceutical related provisions. S. 1890 Defend Trade Secrets Act of 2016, regardng all biopharmaceutical related provisions.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: Commerce, Dept of (DOC); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 1890 (114th), H.R. 9 (114th), S. 1137 (114th)

Medicare/Medicaid MMM

H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions. No Bill, lobbied on price controls for biopharmaceuticals in government health care programs. No Bill, lobbied on the proposed rule on the CMMI Medicare Part B demonstration project. H.R. 5122, legislation to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models,regarding all biopharmaceutical related provisions.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Bills named: H.R. 1416 (114th), H.R. 1190 (114th), H.R. 2570 (114th), H.R. 5122 (114th), H.R. 2 (114th), S. 41 (114th)

Budget/Appropriations BUD

S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions. H.R. 719, Continuing Appropriations Act,regarding all biopharmaceutical related provisions. H.R. 2029, Consolidates Appropriations Act, regarding all biopharmaceutical related provsions. H.R. 3762, Restoring America's Healthcare Freedom Reconciliation Act, regarding all biopharmaceutical related provisions.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: U.S. Trade Representative (USTR); Commerce, Dept of (DOC); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S.Con.Res. 11 (114th), H.R. 719 (114th), H.R. 3762 (114th), H.R. 2029 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.